Molecular MOLN 深 滬
等待開盤 07-11 09:30:00 美东时间
4.0239
0.000
0.00%
華盛通- 最 高4.02
- 今 開3.99
- 成交量 467股
- 最 低 3.99
- 昨 收 4.0239
- 總市值 1.51亿
- 52周最高 5.36
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.4101
- 委 比 73.72%
- 總股本 3751.12万
- 歷史最高 32.04
- 量 比 0.03
- 振 幅 0.75%
- 歷史最低 3.32
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has made significant progress in its BiTAC® platform for developing conditionally active T cell engagers and antibody-drug conjugates. The company plans to prioritize investments in BiTAC-based therapies, aiming to advance VXA-102 to IND/CTA readiness by early 2028. With four BiTAC programs targeting solid tumors and two bispecific ADCs, VERAXA is leveraging its differentiated technology to attract partnerships, especially follo...
07-06 11:00
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
Molecular Partners provided updates on its targeted alpha Radio-DARPin therapeutics pipeline. MP0712, a DLL3-targeted Radio-DARPin with Lead-212, is in Phase 1/2a trials, with dosing ongoing and initial data expected soon, followed by comprehensive results in 2027. A compassionate care program using Ac-225 loaded DLL3 Radio-DARPin (MP0714) has started in South Africa, showcasing DARPins' versatility as isotope-agnostic vectors. MP0726, targeting ...
07-06 05:00
Molecular Partners Q1 EPS $(0.45) Misses $(0.38) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.38) by 18.42 percent. This is a 11.76 percent increase over losses of $(0.51) per share
05-13 04:04
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment
MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein (FAP), which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized
05-01 19:08
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
Reported Sunday, Molecular Partners Nominates MP0632 As First Logic-Gated Switch-DARPin T Cell Engager Candidate For MSLN/EpCAM-Expressing Solid Tumors With Favorable Therapeutic Window At AACR 2026
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin
04-20 16:40
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a Buy and maintains $13 price target.
03-16 19:18
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
